Open Monoclonal Technology Announces OmniRat Antibody License to Pfizer Inc.
Published: Sep 18, 2012
PALO ALTO, Calif.--(BUSINESS WIRE)--Open Monoclonal Technology, Inc. (OMT), a provider of human therapeutic antibody technologies, today announced an agreement whereby Pfizer Inc., a global pharmaceutical company, will use OMT’s OmniRat™ for antibody research and development. OmniRat™ is a platform technology that generates fully human antibodies with great specificity, affinity and manufacturability. Using animals to make human antibodies saves time and money because the immune system optimizes antibodies naturally. Furthermore, OmniRat™ enables developers to skip humanization of animal-derived antibodies or lead-optimization of display candidates.